Master protocols in lung cancer: Experience from Lung Master Protocol

Vincent Lam, Vassiliki Papadimitrakopoulou

Research output: Contribution to journalReview article

Abstract

Purpose of review Contemporary advances in the understanding of the molecular and immunologic basis of metastatic lung cancer have firmly changed its treatment paradigm to a personalized, biomarker-driven approach. However, the majority of lung-cancer patients [especially lung squamous cell carcinoma (LUSC)] still do not have effective targeted therapeutic options. Master protocols, such as Lung-MAP, represent an innovative clinical trial approach designed to accelerate evaluation of novel biomarker-driven therapies. Recent findings Lung-MAP is an umbrella trial for advanced LUSC and has been active since 2014. Cumulative experience from this overarching, multi-institution master protocol has demonstrated that centralized, real-time biomarker screening is feasible and substudy modularity is essential for protocol adaptability in a rapidly changing treatment landscape. In addition, screening and efficacy results from Lung-MAP affirm that LUSC has several putative drivers but remains difficult to effectively treat with targeted therapy. Summary Master protocols are a feasible and efficient approach for evaluating biomarker-driven therapies in lung cancer. As we begin to target less common genomic and immunotherapy subtypes, centrally coordinated clinical trial designs such as Lung-MAP are necessary to rapidly deliver effective therapies to patients, whereas also maximizing the quality of research data obtained.

Original languageEnglish (US)
Pages (from-to)92-97
Number of pages6
JournalCurrent opinion in oncology
Volume30
Issue number2
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Lung Neoplasms
Lung
Biomarkers
Squamous Cell Carcinoma
Therapeutics
Clinical Trials
Immunotherapy
Research

Keywords

  • lung cancer
  • lung squamous cell carcinoma
  • master protocol
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Master protocols in lung cancer : Experience from Lung Master Protocol. / Lam, Vincent; Papadimitrakopoulou, Vassiliki.

In: Current opinion in oncology, Vol. 30, No. 2, 01.03.2018, p. 92-97.

Research output: Contribution to journalReview article

Lam, Vincent ; Papadimitrakopoulou, Vassiliki. / Master protocols in lung cancer : Experience from Lung Master Protocol. In: Current opinion in oncology. 2018 ; Vol. 30, No. 2. pp. 92-97.
@article{ec0d5dc491dd4b82867d97ac86e2351e,
title = "Master protocols in lung cancer: Experience from Lung Master Protocol",
abstract = "Purpose of review Contemporary advances in the understanding of the molecular and immunologic basis of metastatic lung cancer have firmly changed its treatment paradigm to a personalized, biomarker-driven approach. However, the majority of lung-cancer patients [especially lung squamous cell carcinoma (LUSC)] still do not have effective targeted therapeutic options. Master protocols, such as Lung-MAP, represent an innovative clinical trial approach designed to accelerate evaluation of novel biomarker-driven therapies. Recent findings Lung-MAP is an umbrella trial for advanced LUSC and has been active since 2014. Cumulative experience from this overarching, multi-institution master protocol has demonstrated that centralized, real-time biomarker screening is feasible and substudy modularity is essential for protocol adaptability in a rapidly changing treatment landscape. In addition, screening and efficacy results from Lung-MAP affirm that LUSC has several putative drivers but remains difficult to effectively treat with targeted therapy. Summary Master protocols are a feasible and efficient approach for evaluating biomarker-driven therapies in lung cancer. As we begin to target less common genomic and immunotherapy subtypes, centrally coordinated clinical trial designs such as Lung-MAP are necessary to rapidly deliver effective therapies to patients, whereas also maximizing the quality of research data obtained.",
keywords = "lung cancer, lung squamous cell carcinoma, master protocol, targeted therapy",
author = "Vincent Lam and Vassiliki Papadimitrakopoulou",
year = "2018",
month = "3",
day = "1",
doi = "10.1097/CCO.0000000000000433",
language = "English (US)",
volume = "30",
pages = "92--97",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Master protocols in lung cancer

T2 - Experience from Lung Master Protocol

AU - Lam, Vincent

AU - Papadimitrakopoulou, Vassiliki

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Purpose of review Contemporary advances in the understanding of the molecular and immunologic basis of metastatic lung cancer have firmly changed its treatment paradigm to a personalized, biomarker-driven approach. However, the majority of lung-cancer patients [especially lung squamous cell carcinoma (LUSC)] still do not have effective targeted therapeutic options. Master protocols, such as Lung-MAP, represent an innovative clinical trial approach designed to accelerate evaluation of novel biomarker-driven therapies. Recent findings Lung-MAP is an umbrella trial for advanced LUSC and has been active since 2014. Cumulative experience from this overarching, multi-institution master protocol has demonstrated that centralized, real-time biomarker screening is feasible and substudy modularity is essential for protocol adaptability in a rapidly changing treatment landscape. In addition, screening and efficacy results from Lung-MAP affirm that LUSC has several putative drivers but remains difficult to effectively treat with targeted therapy. Summary Master protocols are a feasible and efficient approach for evaluating biomarker-driven therapies in lung cancer. As we begin to target less common genomic and immunotherapy subtypes, centrally coordinated clinical trial designs such as Lung-MAP are necessary to rapidly deliver effective therapies to patients, whereas also maximizing the quality of research data obtained.

AB - Purpose of review Contemporary advances in the understanding of the molecular and immunologic basis of metastatic lung cancer have firmly changed its treatment paradigm to a personalized, biomarker-driven approach. However, the majority of lung-cancer patients [especially lung squamous cell carcinoma (LUSC)] still do not have effective targeted therapeutic options. Master protocols, such as Lung-MAP, represent an innovative clinical trial approach designed to accelerate evaluation of novel biomarker-driven therapies. Recent findings Lung-MAP is an umbrella trial for advanced LUSC and has been active since 2014. Cumulative experience from this overarching, multi-institution master protocol has demonstrated that centralized, real-time biomarker screening is feasible and substudy modularity is essential for protocol adaptability in a rapidly changing treatment landscape. In addition, screening and efficacy results from Lung-MAP affirm that LUSC has several putative drivers but remains difficult to effectively treat with targeted therapy. Summary Master protocols are a feasible and efficient approach for evaluating biomarker-driven therapies in lung cancer. As we begin to target less common genomic and immunotherapy subtypes, centrally coordinated clinical trial designs such as Lung-MAP are necessary to rapidly deliver effective therapies to patients, whereas also maximizing the quality of research data obtained.

KW - lung cancer

KW - lung squamous cell carcinoma

KW - master protocol

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85042425417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042425417&partnerID=8YFLogxK

U2 - 10.1097/CCO.0000000000000433

DO - 10.1097/CCO.0000000000000433

M3 - Review article

C2 - 29329112

AN - SCOPUS:85042425417

VL - 30

SP - 92

EP - 97

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -